Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + KN046 + AG in Advanced Pancreatic Cancer
NCT05832892Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and erfonrilimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
surufatiniberfonrilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05832892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832892.